(Q42634365)

4 November 2017

title

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. (English)

1 reference

4 November 2017

1 reference

1 reference

1 reference

peginterferon alfa-2b

1 reference

1 reference

Fuad Hasan

1

1 reference

4 November 2017

Haifa Asker

2

1 reference

4 November 2017

Jameela Al-Khaldi

3

1 reference

4 November 2017

Iqbal Siddique

4

1 reference

4 November 2017

Misfer Al-Ajmi

5

1 reference

4 November 2017

Salim Owaid

6

1 reference

4 November 2017

Rosh Varghese

7

1 reference

4 November 2017

Basil Al-Nakib

8

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

The American Journal of Gastroenterology

4 November 2017

published in

1 reference

4 November 2017

volume

99

1 reference

4 November 2017

issue

9

1 reference

4 November 2017

page(s)

1733-1737

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40077.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40077.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40077.X

Hepatitis C virus genotyping versus serotyping in Egyptian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40077.X

The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40077.X

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40077.X

Interferon-alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients with persistently normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40077.X

Optimal therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.40077.X

10.1111/J.1572-0241.2004.40077.X

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference